Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

This site uses cookies to store information on your computer. Some cookies on this site are essential and the site won’t work as expected without them. To learn more about cookies and their benefits, please view our cookies policy. You could also decide what kind of cookie the website could use or not use on our cookies settings page.
By closing this message or navigating within the website, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.

Help menu :

  1. Sanofi Worldwide |
     
  2. Our UK Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Site map |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

Our Responsibility

Content :

Access to Health

April 23, 2014

With one-third of the world's population having little or no access to basic healthcare, this inspires us to improve the availability of medicines in parts of the world where they are needed most.

 

Improving access to health is integral to our strategy because our future encompasses developing countries as well as industrialised ones.

 

We act on our commitment to improve access to health through several channels including our Access to Medicines division, the Sanofi Espoir Foundation, collaborations with patient associations and healthcare providers.  These activities encompass a wide range of educational and other healthcare promotion initiatives as well as a supply of medicines.

 

 

We focus on six areas of specialist expertise: malaria, tuberculosis, neglected tropical diseases, mental health, epilepsy, and vaccine preventable disease.

Our strategy is to develop sustainable, economically viable solutions based on tiered pricing.  Although donating medicines may be necessary in exceptional situations, the approach is unsustainable and carries significant disadvantages.  Tiered pricing ensures that 'no profit-no loss' products do not undermine profitable markets.

Improving access to medicines requires more than simply lowering drug prices.  Although we do reduce as much as is consistent with maintaining quality, we also provide expertise and services such as information, education and communication tools to help countries set up their own sustainable programmes.  Rather than just providing the cheapest possible drug, we believe in providing the best possible deal, including complementary services (such as the 'schoolchildren against malaria' initiative in West Africa).

We transfer knowledge and technology to countries that need it, both through our own industrial facilities in Morocco, Brazil and China, and also through high quality clinical trials and projects such as our innovative pharmacovigilance programme in Africa.

As a research-based company, we support the patent system for protecting intellectual property, but are flexible when circumstances dictate.  We seek financial support only for projects that are not economically viable, such as providing fexinidazole for sleeping sickness.

Access to health goes beyond access to medicines, and proceeds from the political commitment of public health decision makers.  As stakeholders in public health, we therefore work with the WHO and a wide range of international NGOs, funding bodies and national health authorities and disease control programmes to implement large scale healthcare initiatives.

Module :

Corporate Information

Corporate Information

 

History

History

Sanofi has a rich history of innovation dating back more than 100 years.